Classic Hairy Cell Leukemia (cHCL) and related conditions are rare, indolent B-cell malignancies characterized by distinctive morphological, immunophenotypic, and molecular features. Over the past decade, major advances in understanding the pathophysiology and molecular underpinnings have reshaped diagnostic and therapeutic approaches. This review synthesizes current knowledge on the cellular origins and signaling pathways that drive cHCL and Hairy Cell Variant (HCL-v)/splenic B-cell lymphoma/leukemia (SBLPN) and other molecular aberrations in disease pathogenesis. We discuss evolving diagnostic modalities, including flow cytometry, immunohistochemistry, and next-generation sequencing, that enhance diagnostic precision and disease monitoring. Additionally, we examine established and emerging therapeutic strategies—from purine nucleoside analogs (PNA) to targeted inhibitors and immunotherapies—that have significantly improved patient outcomes while highlighting challenges such as relapse and treatment resistance. By integrating insights from molecular biology and clinical practice, this review aims to provide a comprehensive understanding of cHCL and related disorders.
Hodgkin’s Lymphoma (HL) affects approximately 8500 individuals annually in the United States. The 5-year relative survival rate has improved to 88.5%, driven by transformative advances in immunotherapy and precision oncology. The integration of Brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs) has redefined treatment paradigms. The phase III SWOG S1826 trial established nivolumab plus doxorubicin, vinblastine, and dacarbazine (N + AVD) as an emerging new standard for advanced-stage HL, achieving a 2-year progression-free survival (PFS) of 92% compared to 83% for BV plus AVD (HR 0.48, 95% CI: 0.33–0.70), with superior safety, particularly in patients over 60. In relapsed/refractory HL, pembrolizumab outperforms BV, with a median PFS of 13.2 versus 8.3 months (HR 0.65, 95% CI: 0.48–0.88), as demonstrated in the KEYNOTE-204 trial. Emerging strategies, including novel ICI combinations, minimal residual disease (MRD) monitoring via circulating tumor DNA (ctDNA), and artificial intelligence (AI)-driven diagnostics, promise to further personalize therapy. This review synthesizes HL’s epidemiology, pathogenesis, diagnostic innovations, and therapeutic advances, highlighting the role of precision medicine in addressing unmet needs and disparities in HL care.
BRAF-directed therapy achieves variable responses across solid tumors, and molecular predictors beyond mutation status remain poorly defined. We retrospectively analyzed 67 patients with BRAF-altered solid tumors across nine histologies treated with BRAF-directed therapy. VAF-defined clonality (≥5 vs <5%) and co-mutational complexity (Simple [0–1], Moderate [2–3], Complex [4+] co-altered pathways) were assessed as predictive biomarkers. Among 60 evaluable patients, ORR was 55% (95% CI: 42–67%). Patients with VAF ≥5% had significantly longer PFS than <5% (mPFS 13.2 vs 7.5 months; HR 0.36, 95% CI: 0.14–0.90; p = 0.021; clonal vs subclonal) and higher ORR (55 vs 33%). Increasing co-mutational complexity was associated with shorter PFS (HR 1.84 per tier; p = 0.009). VAF ≥5% with a simple co-mutational profile was the most favorable subgroup (ORR 70%). External validation in 17,033 BRAF-mutant samples from AACR GENIE v19.0 confirmed reproducibility of VAF distributions across institutions. We propose a hierarchical genomic framework integrating clonality and co-mutational complexity that warrants prospective validation.
25 September 2026 in International Journal of Cancer Care and Delivery
Splenic infarction is a rare and likely underdiagnosed complication of Epstein-Barr virus (EBV) associated infectious mononucleosis (IM). Here we describe an 18-year-old male with persistent severe left-sided abdominal pain found to be EBV positive and have a large splenic infarct, along with a transient decrease in protein C, protein S, and antithrombin III activity levels. He was treated with supportive care, and anticoagulated with heparin and apixaban. We review prior reports and perspectives on underlying pathophysiology, diagnosis, and the management of these cases which likely does not require anticoagulation although may be considered on a per case basis.